

Idiopathic pulmonary fibrosis in adults: diagnosis and management

Clinical guideline

Published: 12 June 2013

Last updated: 23 May 2017

www.nice.org.uk/guidance/cg163

Your responsibility

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the [Yellow Card Scheme](#).

Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should [assess and reduce the environmental impact of implementing NICE recommendations](#) wherever possible.

Contents

Overview	4
Who is it for?	4
Recommendations.....	5
1.1 Awareness of clinical features of idiopathic pulmonary fibrosis	5
1.2 Diagnosis	6
1.3 Information and support	9
1.4 Prognosis	9
1.5 Management	10
1.6 Review and follow-up.....	15
Recommendations for research	16
1 Pulmonary rehabilitation to improve outcomes in people with idiopathic pulmonary fibrosis ...	16
2 Ambulatory oxygen to improve outcomes in idiopathic pulmonary fibrosis	16
3 Anti-reflux therapy as a treatment for idiopathic pulmonary fibrosis.....	17
Context	19
Finding more information and committee details.....	20
Update information	21

This guideline is the basis of QS79.

Overview

This guideline covers diagnosing and managing idiopathic pulmonary fibrosis in people aged 18 and over. It aims to improve the quality of life for people with idiopathic pulmonary fibrosis by helping healthcare professionals to diagnose the condition and provide effective symptom management.

Who is it for?

- Healthcare professionals
- Commissioners and providers
- Adults with suspected or diagnosed idiopathic pulmonary fibrosis and their families and carers

Recommendations

The following guidance is based on the best available evidence. The [full guideline](#) gives details of the methods and the evidence used to develop the guidance.

People have the right to be involved in discussions and make informed decisions about their care, as described in [NICE's information on making decisions about your care](#).

[Making decisions using NICE guidelines](#) explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

1.1 Awareness of clinical features of idiopathic pulmonary fibrosis

1.1.1 Be aware of idiopathic pulmonary fibrosis when assessing a patient with the clinical features listed below and when considering requesting a chest X-ray or referring to a specialist:

- age over 45 years
- persistent breathlessness on exertion
- persistent cough
- bilateral inspiratory crackles when listening to the chest
- clubbing of the fingers
- normal spirometry or impaired spirometry usually with a restrictive pattern but sometimes with an obstructive pattern.

1.2 Diagnosis

1.2.1 Assess everyone with suspected idiopathic pulmonary fibrosis by:

- taking a detailed history, carrying out a clinical examination (see [recommendation 1.1.1 for clinical features](#)) and performing blood tests to help exclude alternative diagnoses, including lung diseases associated with environmental and occupational exposure, with connective tissue diseases and with drugs **and**
- performing lung function testing (spirometry and gas transfer) **and**
- reviewing results of chest X-ray **and**
- performing CT of the thorax (including high-resolution images).

1.2.2 Diagnose idiopathic pulmonary fibrosis only with the consensus of the multidisciplinary team (listed in table 1), based on:

- the clinical features, lung function and radiological findings (see recommendation 1.2.1)
- pathology when indicated (see recommendation 1.2.4).

1.2.3 At each stage of the diagnostic care pathway the multidisciplinary team should consist of a minimum of the healthcare professionals listed in table 1, all of whom should have expertise in interstitial lung disease.

Table 1 Minimum composition of multidisciplinary team involved in diagnosing idiopathic pulmonary fibrosis

Stage of diagnostic care pathway	Multidisciplinary team composition (all healthcare professionals should have expertise in interstitial lung disease)
<p>After clinical evaluation, baseline lung function and CT</p>	<ul style="list-style-type: none"> • Consultant respiratory physician • Consultant radiologist • Interstitial lung disease specialist nurse • Multidisciplinary team coordinator
<p>When considering performing bronchoalveolar lavage, and/or transbronchial biopsy or surgical lung biopsy</p> <p>Only some patients will have bronchoalveolar lavage or transbronchial biopsy but they may be being considered for surgical lung biopsy</p>	<ul style="list-style-type: none"> • Consultant respiratory physician • Consultant radiologist • Consultant histopathologist • Thoracic surgeon as appropriate • Interstitial lung disease specialist nurse • Multidisciplinary team coordinator

Stage of diagnostic care pathway	Multidisciplinary team composition (all healthcare professionals should have expertise in interstitial lung disease)
When considering results of bronchoalveolar lavage, transbronchial biopsy or surgical lung biopsy	<ul style="list-style-type: none"> • Consultant respiratory physician • Consultant radiologist • Consultant histopathologist • Interstitial lung disease specialist nurse • Multidisciplinary team coordinator

See the [full guideline for more information on the expertise of the multidisciplinary team](#).

If a confident diagnosis cannot be made

1.2.4 If the multidisciplinary team cannot make a confident diagnosis from clinical features, lung function and radiological findings, consider:

- bronchoalveolar lavage or transbronchial biopsy **and/or**
- surgical lung biopsy, with the agreement of the thoracic surgeon.

1.2.5 Discuss with the person who may have idiopathic pulmonary fibrosis:

- the potential benefits of having a confident diagnosis compared with the uncertainty of not having a confident diagnosis **and**
- the increased likelihood of obtaining a confident diagnosis with surgical biopsy compared with bronchoalveolar lavage or transbronchial biopsy **and**
- the increased risks of surgical biopsy compared with bronchoalveolar lavage or transbronchial biopsy.

1.2.6 When considering bronchoalveolar lavage, transbronchial biopsy or surgical lung biopsy take into account:

- the likely differential diagnoses **and**
- the person's clinical condition, including any comorbidities.

1.2.7 If a confident diagnosis cannot be made continue to review the person under specialist care.

1.3 Information and support

- 1.3.1 The consultant respiratory physician or interstitial lung disease specialist nurse should provide accurate and clear information (verbal and written) to people with idiopathic pulmonary fibrosis, and their families and carers with the person's consent. This should include information about investigations, diagnosis and management.
- 1.3.2 NICE has produced guidance on the components of good patient experience in adult NHS services. Follow the [recommendations in NICE's guideline on patient experience in adult NHS services](#).
- 1.3.3 An interstitial lung disease specialist nurse should be available at all stages of the care pathway to provide information and support to people with idiopathic pulmonary fibrosis and their families and carers with the person's consent.
- 1.3.4 Offer advice, support and treatment to aid smoking cessation to all people with idiopathic pulmonary fibrosis who also smoke, in line with [NICE's guideline on tobacco](#).

1.4 Prognosis

- 1.4.1 Measure the initial rate of decline in the person's condition, which may predict subsequent prognosis, by using lung function test results (spirometry and gas transfer) at:
- diagnosis **and**

- 6 months and 12 months after diagnosis. Repeat the lung function tests at shorter intervals if there is concern that the person's condition is deteriorating rapidly.
- 1.4.2 Discuss prognosis with people with idiopathic pulmonary fibrosis in a sensitive manner and include information on:
- the severity of the person's disease and average life expectancy
 - the varying courses of disease and range of survival
 - management options available.
- 1.4.3 Do not use the 6-minute walk distance at diagnosis to estimate prognosis. (The 6-minute walk test may be useful for other purposes, see recommendation 1.5.1.)

1.5 Management

Pulmonary rehabilitation

- 1.5.1 Assess people with idiopathic pulmonary fibrosis for pulmonary rehabilitation at the time of diagnosis. Assessment may include a 6-minute walk test (distance walked and oxygen saturation measured by pulse oximetry) and a quality-of-life assessment.

Be aware that some pulse oximeters can underestimate or overestimate oxygen saturation levels, especially if the saturation level is borderline. Overestimation has been reported in people with dark skin. See also the [NHS England Patient Safety Alert on the risk of harm from inappropriate placement of pulse oximeter probes](#).

- 1.5.2 Repeat the assessment for pulmonary rehabilitation for people with idiopathic pulmonary fibrosis at 6-month or 12-month intervals.
- 1.5.3 If appropriate after each assessment, offer pulmonary rehabilitation including exercise and educational components tailored to the needs of people with

idiopathic pulmonary fibrosis in general.

- 1.5.4 Pulmonary rehabilitation should be tailored to the individual needs of each person with idiopathic pulmonary fibrosis. Sessions should be held somewhere that is easy for people with idiopathic pulmonary fibrosis to get to and has good access for people with disabilities.

Best supportive care

- 1.5.5 Offer best supportive care to people with idiopathic pulmonary fibrosis from the point of diagnosis. Best supportive care should be tailored to disease severity, rate of progression, and the person's preference, and should include if appropriate:

- information and support (see [recommendation 1.3.1 in the section on information and support](#))
- symptom relief
- management of comorbidities
- withdrawal of therapies suspected to be ineffective or causing harm
- end of life care.

- 1.5.6 If the person is breathless on exertion consider assessment for:

- the causes of breathlessness and degree of hypoxia **and**
- ambulatory oxygen therapy and long-term oxygen therapy **and/or**
- pulmonary rehabilitation.

- 1.5.7 If the person is breathless at rest consider:

- assessment for the causes of breathlessness and degree of hypoxia **and**
- assessment for additional ambulatory oxygen therapy and long-term oxygen therapy **and**

- the person's psychosocial needs and offering referral to relevant services such as palliative care services **and**
 - pharmacological symptom relief with benzodiazepines and/or opioids.
- 1.5.8 Assess the oxygen needs of people who have been hospitalised with idiopathic pulmonary fibrosis before they are discharged.
- 1.5.9 If the person has a cough consider:
- treatment for causes other than idiopathic pulmonary fibrosis (such as gastro-oesophageal reflux disease, post-nasal drip)
 - treating with opioids if the cough is debilitating
 - discussing treatment with thalidomide with a consultant respiratory physician with expertise in interstitial lung disease if the cough is intractable.
- At the time of publication (June 2013), thalidomide did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the [General Medical Council's Good practice in prescribing and managing medicines and devices](#) for further information.
- 1.5.10 Ensure people with idiopathic pulmonary fibrosis, and their families and carers, have access to the full range of services offered by palliative care teams. Ensure there is collaboration between the healthcare professionals involved in the person's care, community services and the palliative care team.

Disease-modifying pharmacological interventions

- 1.5.11 Nintedanib is recommended as an option in NICE technology appraisal guidance for treating idiopathic pulmonary fibrosis in people with forced vital capacity (FVC) above 80% predicted. For full details, see the [guidance on nintedanib \(TA864, 2023\)](#).

1.5.12 For medicines recommended as options in NICE technology appraisal guidance for treating idiopathic pulmonary fibrosis in people with FVC between 50% and 80% of predicted, see the guidance on:

- [pirfenidone \(TA504, 2018\)](#)
- [nintedanib \(TA379, 2016\)](#).

1.5.13 Do not use any of the medicines below, either alone or in combination, to modify disease progression in idiopathic pulmonary fibrosis:

- ambrisentan
- azathioprine
- bosentan
- co-trimoxazole
- mycophenolate mofetil
- prednisolone
- sildenafil
- warfarin.

1.5.14 Advise the person that oral N-acetylcysteine is used for managing idiopathic pulmonary fibrosis, but its benefits are uncertain.

At the time of publication (June 2013), N-acetylcysteine did not have a UK marketing authorisation. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the [General Medical Council's Good practice in prescribing and managing medicines and devices](#) for further information.

1.5.15 If people with idiopathic pulmonary fibrosis are already using prednisolone or azathioprine, discuss the potential risks and benefits of discontinuing, continuing or altering therapy.

1.5.16 Manage any comorbidities according to best practice. For gastro-oesophageal

reflux disease, see [NICE's guideline on gastro-oesophageal reflux disease and dyspepsia in adults](#).

Lung transplantation

1.5.17 Discuss lung transplantation as a treatment option for people with idiopathic pulmonary fibrosis who do not have absolute contraindications. Discussions should:

- take place between 3 and 6 months after diagnosis or sooner if clinically indicated
- be supported by an interstitial lung disease specialist nurse
- include the risks and benefits of lung transplantation
- involve the person's family and carers with the person's consent.

(See the [recommendations in the section on best supportive care](#).)

1.5.18 Refer people with idiopathic pulmonary fibrosis for lung transplantation assessment if they wish to explore lung transplantation and if there are no absolute contraindications. Ask the transplant centre for an initial response within 4 weeks.

Ventilation

1.5.19 A respiratory physician or specialist nurse with an interest in interstitial lung disease should discuss the poor outcomes associated with mechanical ventilation (including non-invasive mechanical ventilation) for respiratory failure with people with idiopathic pulmonary fibrosis. These discussions should ideally take place between 3 to 6 months after diagnosis or sooner if clinically indicated. (See the [recommendations in the section on best supportive care](#).)

1.5.20 Do not routinely offer mechanical ventilation (including non-invasive mechanical ventilation) to people with idiopathic pulmonary fibrosis who develop life-

threatening respiratory failure.

1.6 Review and follow-up

1.6.1 In follow-up appointments for people with idiopathic pulmonary fibrosis:

- assess lung function
- assess for oxygen therapy
- assess for pulmonary rehabilitation
- offer smoking cessation advice, in line with [NICE's guideline on tobacco](#)
- identify exacerbations and previous respiratory hospital admissions
- consider referral for assessment for lung transplantation in people who do not have absolute contraindications (see the [recommendations in the section on lung transplantation](#))
- consider psychosocial needs and referral to relevant services as appropriate
- consider referral to palliative care services
- assess for comorbidities (which may include anxiety, bronchiectasis, depression, diabetes, dyspepsia, ischaemic heart disease, lung cancer and pulmonary hypertension).

1.6.2 Consider follow-up of people with idiopathic pulmonary fibrosis:

- every 3 months or sooner if they are showing rapid disease progression or rapid deterioration of symptoms **or**
- every 6 months or sooner if they have steadily progressing disease **or**
- initially every 6 months if they have stable disease and then annually if they have stable disease after 1 year.

Recommendations for research

The Guideline Development Group has made the following recommendations for research, based on its review of evidence, to improve NICE guidance and patient care in the future. The Guideline Development Group's full set of recommendations for research is detailed in the [full guideline](#).

1 Pulmonary rehabilitation to improve outcomes in people with idiopathic pulmonary fibrosis

Does pulmonary rehabilitation improve outcomes for people with idiopathic pulmonary fibrosis?

Why this is important

There is evidence that people with idiopathic pulmonary fibrosis may benefit from pulmonary rehabilitation. However this evidence is mostly derived from programmes designed principally for people with chronic obstructive pulmonary disease. It is likely that the needs of people with idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease differ. Randomised controlled trials should be carried out to determine the effects of pulmonary rehabilitation programmes tailored to idiopathic pulmonary fibrosis, compared with currently offered pulmonary rehabilitation programmes, on quality of life, walking distance and lung function with analysis adjusting for confounding factors appropriately. Trials should analyse benefits of the different aspects of pulmonary rehabilitation including the components, setting and location of the programme, and healthcare resources involved. End points may include: 6-minute walk distance; breathlessness score; a measure of health-related quality of life (ideally employing a tool validated in people with idiopathic pulmonary fibrosis); mortality (all-cause and idiopathic pulmonary fibrosis-related); hospitalisation (all-cause, non-elective and idiopathic pulmonary fibrosis-related); lung function (vital capacity and diffusion capacity for carbon monoxide). Studies should be of sufficient power and duration and include a health economic evaluation.

2 Ambulatory oxygen to improve outcomes in

idiopathic pulmonary fibrosis

Does ambulatory oxygen improve outcomes in idiopathic pulmonary fibrosis?

Why this is important

People with idiopathic pulmonary fibrosis frequently demonstrate a fall in oxygen saturation during exercise even though they are not hypoxic at rest. In such people, ambulatory oxygen is often provided to improve exercise capacity, enhance mobility and enable activities of daily living in order to improve quality of life. However, there are no randomised controlled trials to demonstrate that ambulatory oxygen therapy is effective in achieving these aims in patients with idiopathic pulmonary fibrosis. A randomised controlled trial should be conducted to determine the effects of ambulatory oxygen on quality of life in people with idiopathic pulmonary fibrosis and consideration given to the use of a placebo arm. This should include a standardised protocol for assessing exercise such as the 6-minute walk test. The end points may include 6-minute walk distance; breathlessness score; a measure of health-related quality of life (ideally employing a tool validated in idiopathic pulmonary fibrosis patients). Phase III trials should have a duration of greater than 12 months and include a health economic evaluation.

3 Anti-reflux therapy as a treatment for idiopathic pulmonary fibrosis

Is anti-reflux therapy an effective treatment for idiopathic pulmonary fibrosis?

Why this is important

There is evidence from observational studies, and uncontrolled interventional trials, that microaspiration of gastric/oesophageal contents contribute to disease progression, and perhaps even cause idiopathic pulmonary fibrosis. There have been no randomised controlled trials of anti-reflux therapy in idiopathic pulmonary fibrosis but proton-pump inhibitors are often prescribed for symptoms of acid-reflux. A randomised, placebo-controlled trial of adequate power and duration of greater than 12 months should be undertaken to determine the benefits and side effects of anti-reflux therapy, including proton pump inhibition in people with a confirmed diagnosis of idiopathic pulmonary fibrosis. Appropriate end points may include mortality (all-cause and idiopathic pulmonary fibrosis-related); hospitalisation (all-cause, non-elective and idiopathic pulmonary fibrosis-

related); lung function (vital capacity and diffusion capacity for carbon monoxide); 6-minute walk distance; breathlessness score; a measure of health-related quality of life (ideally employing a tool validated in idiopathic pulmonary fibrosis patients). Phase III trials should include a health economic evaluation.

Context

Idiopathic pulmonary fibrosis is a chronic, progressive fibrotic interstitial lung disease of unknown origin. It is a difficult disease to diagnose and often requires the collaborative expertise of a consultant respiratory physician, radiologist and histopathologist to reach a consensus diagnosis. Most people with idiopathic pulmonary fibrosis experience symptoms of breathlessness, which may initially be only on exertion. Cough, with or without sputum, is a common symptom. Over time, these symptoms are associated with a decline in lung function, reduced quality of life and ultimately death.

The median survival for people with idiopathic pulmonary fibrosis in the UK is approximately 3 years from the time of diagnosis. However, about 20% of people with the disease survive for more than 5 years. The rate of disease progression can vary greatly. A person's prognosis is difficult to estimate at the time of diagnosis and may only become apparent after a period of careful follow-up.

This guideline contains recommendations on the diagnosis of idiopathic pulmonary fibrosis and delivery of care to people with idiopathic pulmonary fibrosis, from initial suspicion of the disease and referral to a consultant respiratory physician, to best supportive care and disease-modifying treatments.

The guideline will assume that prescribers will use a drug's summary of product characteristics to inform decisions made with individual patients.

This guideline recommends some drugs for indications for which they do not have a UK marketing authorisation at the date of publication, if there is good evidence to support that use. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. The patient (or those with authority to give consent on their behalf) should provide informed consent, which should be documented. See the [General Medical Council's Good practice in prescribing and managing medicines and devices](#) for further information. Where recommendations have been made for the use of drugs outside their licensed indications ('off-label use'), these drugs are noted in the recommendations.

Finding more information and committee details

To find NICE guidance on related topics, including guidance in development, see the [NICE topic page on respiratory conditions](#).

For full details of the evidence and the guideline committee's discussions, see the [full guideline](#). You can also find information about [how the guideline was developed](#), including details of the committee.

NICE has produced [tools and resources to help you put this guideline into practice](#). For general help and advice on putting our guidelines into practice, see [resources to help you put NICE guidance into practice](#).

Update information

May 2017: Recommendation 1.5.12 was amended to add a link to [NICE's technology appraisal guidance on nintedanib for the treatment of idiopathic pulmonary fibrosis](#). Two outdated recommendations for research were removed.

Minor changes since publication

September 2024: We added links to relevant technology appraisal guidance in the [section on disease-modifying pharmacological interventions](#).

October 2022: We added text to indicate that pulse oximetry may be less reliable in people with dark skin. We also added a link to the NHS patient safety alert on the risk of harm from inappropriate placement of pulse oximeter probes. See recommendation 1.5.1.

ISBN: 978-1-4731-0179-1